Verscend Technologies appoints VP of client services

Healthcare data company Verscend Technologies has appointed a new senior vice president of client services as it focuses on improving its offerings to customers.

Taking on the new role is Joe Morrissey, who will be responsible for managing the client services team to meet the needs of Verscend’s 350 clients, the company said in a statement.

“Joe has decades of leadership and payer experience partnering with customers to address complex healthcare challenges,” said CEO Emad Rizk, MD, in a statement. “His commitment to customers and execution on value will be a tremendous asset to our growing leadership team. As Verscend continues to stay ahead of the ever-changing healthcare industry, Joe will be a strong advocate for our clients and laser-focused on building a team that is centered on meeting and exceeding their expectations.”

Morrissey previously worked at McKesson, a pharmaceutical retailer based in San Francisco, where he held numerous leadership roles. He was most recently the vice president of account management, a position in which he managed a team that oversaw their payer and government clients.

“Verscend has a fantastic reputation for delivering actionable healthcare data analytics and as a market leader in quality measurements,” Morrissey said. “I’m happy to be joining this team.”

Katherine Davis,

Senior Writer

As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.